Wuxi And Qiagen Form Biomarker Partnership In Shanghai
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - WuXi Pharmatech, China's top contract research organization, and Qiagen, the leading global provider of sample and assay technologies, announced Jan. 11 that they reached an agreement to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets for their respective client bases
You may also be interested in...
Qiagen Forms JV With Shanghai's Bio-X Center For Translational Research In China
Qiagen forms JV with Shanghai Jiao Tong University for translational research to focus on biomarkers, diagnostics for developing drugs specifically for Asians.
China's CRO Industry Pulling Out All Stops In The Year Of The Tiger (Part 1 of 2)
SHANGHAI - By the end of 2009 there were roughly 500 contract research organizations in China, most of which are small registration consultants, and about 150 execute research work. Driven by the trend to offshore R&D work from big pharmas and the double digital growth of the Chinese market, the number of CRO companies is expected to increase further and offer broader services in the upcoming Chinese Year of The Tiger
Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments